RxDoctor Payments Data

Poras Patel

Hematology & Oncology · Huntersville, NCNPI 1669876447

Payments from drug & device makers

$21,313in general payments, 2019–2025

Across 612 payments — averaging $34.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Labcorp Holdings Inc.$3K
  • Novartis$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Pharmacosmos Therapeutics Inc.$2K
  • Pfizer$752
  • AstraZeneca$685
  • plus $9K from 54 others

What the payments were for

  • Consulting fees$1,5457%
  • Speaking & faculty fees$5,30025%
  • Travel & lodging$1721%
  • Food & beverage$12,42258%
  • Education$3432%
  • Other$1,5317%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Labcorp Holdings Inc.3$3,294
Novartis78$2,750
E.r. Squibb & Sons, L.L.C.51$2,415
Pharmacosmos Therapeutics Inc.5$2,374
Pfizer40$752
AstraZeneca(2 entities)25$685
Merck34$651
Johnson & Johnson(2 entities)23$628
Astellas Pharma US Inc19$483
Eisai Inc.20$404
Gilead(2 entities)17$373
Takeda Pharmaceuticals U.S.A., Inc.11$369
Bristol Myers Squibb15$283
Daiichi Sankyo Inc.13$281
Amgen13$280
Array Biopharma Inc17$255
Genentech USA, Inc.12$252
Lilly USA, LLC13$243
Sanofi10$240
Exelixis Inc.10$239
AbbVie11$235
GSK10$207
Incyte Corporation9$205
Servier Pharmaceuticals LLC9$174
Pharmaessentia USA Corporation6$167
Bayer7$165
Sobi, Inc8$161
Seagen Inc.6$158
Karyopharm Therapeutics Inc.4$121
Mirati Therapeutics, Inc.4$116
Adaptive Biotechnologies Corporation5$112
Ipsen Biopharmaceuticals, Inc4$109
Jazz Pharmaceuticals Inc.5$108
Global Blood Therapeutics, Inc.5$101
Secura Bio, Inc.7$97
Beigene USA, Inc.5$94
Regeneron Healthcare Solutions, Inc.3$90
Tersera Therapeutics LLC3$88
EMD Serono, Inc.4$85
Foundation Medicine, Inc.4$85
Pharmacyclics LLC, An Abbvie Company5$82
TG Therapeutics, Inc.3$81
Coherus Oncology, Inc.4$72
Alnylam Pharmaceuticals Inc.3$67
Epizyme, Inc.3$66
Tempus AI, Inc2$65
Immunogen, Inc.3$65
Menarini Silicon Biosystems, Inc.3$65
Boehringer Ingelheim3$61
Geron Corporation2$54
Acrotech Biopharma Inc.2$44
Beone Medicines USA, Inc.2$43
Rigel Pharmaceuticals, Inc.2$40
CTI Biopharma Corp.2$39
Dova Pharmaceuticals2$37
Organon1$34
Legend Biotech USA Inc.1$34
Fennec Pharmaceuticals, Inc.1$33
Shield Therapeutics Inc2$31
Stemline Therapeutics Inc.1$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,313 in reported general payments places this provider in the 60th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$2,161,817
Medicare patients
297
Services billed
95,777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide20$272,843
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5018$157,138
Udenyca AutoinjectorPegfilgrastim-Cbqv21$122,127
OctagamImmun Globg(Igg)/Malt/Iga Ov5016$116,190
RuxienceRituximab-Pvvr18$106,021
MvasiBevacizumab-Awwb22$103,266
Abiraterone Acetate25$97,513
TruximaRituximab-Abbs13$70,788
ProcritEpoetin Alfa67$63,377
EliquisApixaban64$55,599
ProliaDenosumab27$46,091
XgevaDenosumab13$39,747
Lupron DepotLeuprolide Acetate14$26,881
XareltoRivaroxaban15$14,937
CinvantiAprepitant22$10,245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Ruxience, Eliquis$752$277,80998 claims
Astellas Pharma US IncXtandi$483$272,84320 claims
AmgenMvasi, Prolia, Xgeva$280$189,10462 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$369$157,13818 claims
Johnson & JohnsonProcrit, Xarelto$628$78,31582 claims
AbbVieLupron Depot$235$26,88114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 358 hematology & oncology providers in North Carolina.

Other hematology & oncology in Huntersville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →